A Phase 3 interventional study of Guselkumab and Placebo in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 142 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.
Among the 29 studies testing guselkumab in Psoriasis, this one has the largest enrollment, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,048 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 2nd largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2017, is one of 36 in phase 3, and was the 51st registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
3 of the studies testing guselkumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07532486Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis | 2027-07-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing guselkumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.
The study consists of Screening Phase(4 weeks before administration of study drug),Active Treatment Phase(Week 0-Week 44),Follow Up Phase(Week 44-Week 56).During various study periods,safety assessments(example[e.g] recording of adverse events,Vital signs,Tuberculosis evaluation,Chest radiograph,Urine pregnancy Test);Efficacy assessments(e.g IGA,PASI);Clinical Laboratory Assessments(e.g haematology,chemistry);Biomarkers/Genetic evaluations,will be performed per the study procedures.The primary hypotheses are that guselkumab treatment is non-inferior to secukinumab as assessed by proportion of participants achieving PASI 90 response at Week 48 with noninferiority margin of 10% and,once non-inferiority is established,that guselkumab is superior to secukinumab as assessed by proportion of participants achieving PASI 90 response at Week 48.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
Drug: Guselkumab · Drug: Placebo
Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Drug: Secukinumab
Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Also known as: Cosentyx
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
Time frame: Week 48
Percentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 48
Percentage of participants who achieved PASI-75 response at both Week 12 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Time frame: Week 12 and 48
Percentage of Participants Who Achieved a PASI-90 Response at Week 12
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Due to failing to achieve superiority of prior secondary endpoint, no formal statistical testing was performed for endpoints from this point onwards.
Time frame: Week 12
Percentage of Participants Who Achieved a PASI-75 Response at Week 12
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Time frame: Week 12
Percentage of Participants Who Achieved a PASI-100 Response at Week 48
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 100 response was defined as 100% reduction in PASI relative to baseline.
Time frame: Week 48
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 48
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 48
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 48
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 48
Percentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 48
Percentage of participants who achieved PASI-90 response at both Week 16 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.
Time frame: Week 16 and 48
Percentage of Participants Who Achieved a PASI-75 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Time frame: Week 16
Percentage of Participants Who Achieved a PASI-90 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.
Time frame: Week 16
Percentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 48
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Percentage of participants who achieved a PASI-90 response at all 7 visits from Week 24 to 48 (Week 24, 28, 32, 36, 40, 44 and 48) was reported.
Time frame: Week 24 up to Week 48
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 16
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 16
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 12
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 12
Percentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 12
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Time frame: Week 48
Percentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90 percent (%) reduction in PASI relative to baseline.
Time frame: Week 48
Percentage of Participants Who Achieved PASI Response (PASI 100, PASI-90, PASI-75 and PASI-50) Over Time From Week 1 to Week 56
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively.
Time frame: Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56
Percentage of Participants With IGA Responses Through Week 56
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56
Percent Improvement From Baseline in PASI Through Week 56
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
Time frame: Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and Week 56
| Milestone | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Started | 534 | 514 |
| Treated | 534 | 511 |
| Completed | 507 | 466 |
| Not completed | 27 | 48 |
| Withdrew: Adverse event | 9 | 11 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Lack of efficacy | 2 | 7 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 7 | 19 |
| Withdrew: Protocol violation | 2 | 6 |
| Withdrew: Non-compliance | 2 | 0 |
| Withdrew: Other | 2 | 2 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48 | 84.5 | 70.0 |
Percentage of participants who achieved PASI-75 response at both Week 12 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 48 | 84.6 | 80.2 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Due to failing to achieve superiority of prior secondary endpoint, no formal statistical testing was performed for endpoints from this point onwards.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-90 Response at Week 12 | 69.1 | 76.1 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-75 Response at Week 12 | 89.3 | 91.6 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 100 response was defined as 100% reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-100 Response at Week 48 | 58.2 | 48.4 |
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 48 | 62.2 | 50.4 |
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 48 | 85.0 | 74.9 |
Percentage of participants who achieved PASI-90 response at both Week 16 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 48 | 72.3 | 64.4 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-75 Response at Week 16 | 92.7 | 92.8 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-90 Response at Week 16 | 78.5 | 79.6 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Percentage of participants who achieved a PASI-90 response at all 7 visits from Week 24 to 48 (Week 24, 28, 32, 36, 40, 44 and 48) was reported.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 48 | 71.0 | 61.5 |
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 16 | 86.7 | 86.6 |
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 12 | 85.6 | 86.4 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 12 | 94.8 | 87.5 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90 percent (%) reduction in PASI relative to baseline.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 16 | 92.1 | 80.9 |
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively.
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Week 1: 100% improvement | 0 | 0 |
| Week 1: >=90% improvement | 0 | 0 |
| Week 1: >=75% improvement | 2.1 | 1.8 |
| Week 1: >=50% improvement | 10.7 | 12.8 |
| Week 2: 100% improvement | 0.2 | 0.6 |
| Week 2: >=90% improvement | 1.1 | 2.7 |
| Week 2: >=75% improvement | 6.4 | 11.5 |
| Week 2: >=50% improvement | 30.9 | 42.0 |
| Week 3: 100% improvement | 1.7 | 1.6 |
| Week 3: >=90% improvement | 5.6 | 8.6 |
| Week 3: >=75% improvement | 19.5 | 28.4 |
| Week 3: >=50% improvement | 56.4 | 66.9 |
| Week 4: 100% improvement | 4.1 | 5.1 |
| Week 4: >=90% improvement | 13.1 | 21.8 |
| Week 4: >=75% improvement | 39.3 | 50.2 |
| Week 4: >=50% improvement | 73.4 | 85.4 |
| Week 8: 100% improvement | 20.0 | 27.2 |
| Week 8: >=90% improvement | 48.7 | 62.1 |
| Week 8: >=75% improvement | 76.4 | 86.2 |
| Week 8: >=50% improvement | 95.3 | 96.9 |
| Week 12: 100% improvement | 37.8 | 42.0 |
| Week 12: >=90% improvement | 69.1 | 76.1 |
| Week 12: >=75% improvement | 89.3 | 91.6 |
| Week 12: >=50% improvement | 96.8 | 96.1 |
| Week 16: 100% improvement | 47.8 | 46.1 |
| Week 16: >=90% improvement | 78.5 | 79.6 |
| Week 16: >=75% improvement | 92.7 | 92.8 |
| Week 16: >=50% improvement | 97.6 | 96.3 |
| Week 20: 100% improvement | 51.3 | 48.6 |
| Week 20: >=90% improvement | 80.1 | 81.1 |
| Week 20: >=75% improvement | 93.6 | 92.4 |
| Week 20: >=50% improvement | 97.6 | 95.1 |
| Week 24: 100% improvement | 54.7 | 50.4 |
| Week 24: >=90% improvement | 83.1 | 78.2 |
| Week 24: >=75% improvement | 94.2 | 90.3 |
| Week 24: >=50% improvement | 97.8 | 93.0 |
| Week 28: 100% improvement | 57.1 | 51.0 |
| Week 28: >=90% improvement | 85.4 | 77.2 |
| Week 28: >=75% improvement | 94.0 | 90.3 |
| Week 28: >=50% improvement | 97.2 | 93.0 |
| Week 32: 100% improvement | 57.5 | 50.2 |
| Week 32:>=90 % improvement | 84.8 | 77.4 |
| Week 32: >=75% improvement | 94.0 | 89.3 |
| Week 32: >=50% improvement | 97.0 | 93.0 |
| Week 36: 100% improvement | 58.6 | 50.0 |
| Week 36: >=90% improvement | 84.5 | 75.7 |
| Week 36: >=75% improvement | 93.6 | 87.0 |
| Week 36: >=50% improvement | 97.2 | 92.2 |
| Week 40: 100% improvement | 58.2 | 48.6 |
| Week 40: >=90% improvement | 84.6 | 73.7 |
| Week 40: >=75% improvement | 92.9 | 85.8 |
| Week 40: >=50% improvement | 95.9 | 90.9 |
| Week 44: 100% improvement | 58.6 | 49.4 |
| Week 44: >=90% improvement | 84.1 | 72.6 |
| Week 44: >=75% improvement | 92.3 | 85.2 |
| Week 44: >=50% improvement | 94.2 | 91.4 |
| Week 48: 100% improvement | 58.2 | 48.4 |
| Week 48: >=90% improvement | 84.5 | 70.0 |
| Week 48: >=75% improvement | 92.1 | 83.5 |
| Week 48: >=50% improvement | 94.0 | 89.3 |
| Week 56: 100% improvement | 50.4 | 27.0 |
| Week 56: >=90% improvement | 77.3 | 51.4 |
| Week 56: >=75% improvement | 88.0 | 70.4 |
| Week 56: >=50% improvement | 91.0 | 82.1 |
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| Percentage of participants | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Week 1: cleared (0) | 0 | 0 |
| Week 1: cleared (0) or minimal (1) | 3.4 | 2.5 |
| Week 1: mild or better (=<2) | 27.2 | 34.2 |
| Week 2: cleared (0) | 0.2 | 0.8 |
| Week 2: cleared (0) or minimal (1) | 12.4 | 20.2 |
| Week 2: mild or better (=<2) | 54.1 | 63.8 |
| Week 3: cleared (0) | 2.6 | 3.3 |
| Week 3: cleared (0) or minimal (1) | 27.2 | 39.9 |
| Week 3: mild or better (=<2) | 75.3 | 82.5 |
| Week 4: cleared (0) | 6.7 | 9.7 |
| Week 4: cleared (0) or minimal (1) | 44.2 | 59.3 |
| Week 4: mild or better (=<2) | 85.6 | 92.2 |
| Week 8: cleared (0) | 29.2 | 35.8 |
| Week 8: cleared (0) or minimal (1) | 76.6 | 83.5 |
| Week 8: mild or better (=<2) | 96.3 | 96.3 |
| Week 12: cleared (0) | 46.3 | 50.2 |
| Week 12: cleared (0) or minimal (1) | 85.6 | 86.4 |
| Week 12: mild or better (=<2) | 96.8 | 95.3 |
| Week 16: cleared (0) | 55.4 | 53.5 |
| Week 16: mild or better (=<2) | 96.8 | 94.7 |
| Week 16: cleared (0) or minimal (1) | 86.7 | 86.6 |
| Week 20: cleared (0) | 56.9 | 53.9 |
| Week 20: cleared (0) or minimal (1) | 87.8 | 85.6 |
| Week 20: mild or better (=<2) | 95.3 | 93.2 |
| Week 24: cleared (0) | 61.0 | 56.0 |
| Week 24: cleared (0) or minimal (1) | 88.6 | 82.7 |
| Week 24: mild or better (=<2) | 96.3 | 91.6 |
| Week 28: cleared (0) | 62.2 | 56.2 |
| Week 28: cleared (0) or minimal (1) | 87.8 | 82.9 |
| Week 28: mild or better (<=2) | 95.5 | 90.9 |
| Week 32: cleared (0) | 63.1 | 54.5 |
| Week 32: cleared (0) or minimal (1) | 88.6 | 81.5 |
| Week 32: mild or better (=<2) | 95.5 | 90.5 |
| Week 36: cleared (0) | 60.7 | 53.7 |
| Week 36: cleared (0) or minimal (1) | 86.5 | 79.6 |
| Week 36: mild or better (=<2) | 95.5 | 88.9 |
| Week 40: cleared (0) | 63.1 | 52.3 |
| Week 40: cleared (0) or minimal (1) | 86.3 | 78.0 |
| Week 40: mild or better (=<2) | 93.6 | 87.9 |
| Week 44: cleared (0) | 62.2 | 51.9 |
| Week 44: cleared (0) or minimal (1) | 86.0 | 76.5 |
| Week 44: mild or better (=<2) | 92.3 | 87.5 |
| Week 48: cleared (0) | 62.2 | 50.4 |
| Week 48: cleared (0) or minimal (1) | 85.0 | 74.9 |
| Week 48: mild or better (=<2) | 92.7 | 86.8 |
| Week 56: cleared (0) | 54.3 | 29.4 |
| Week 56: cleared (0) or minimal (1) | 78.8 | 58.2 |
| Week 56: mild or better (=<2) | 87.5 | 76.3 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
| Percent improvement | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Week 1 | 20.30 ± 20.743 | 24.72 ± 20.711 |
| Week 2 | 37.85 ± 23.567 | 44.56 ± 23.600 |
| Week 3 | 52.76 ± 24.186 | 60.57 ± 21.871 |
| Week 4 | 64.63 ± 22.862 | 72.80 ± 19.478 |
| Week 8 | 84.36 ± 17.278 | 89.40 ± 13.579 |
| Week 12 | 90.85 ± 14.484 | 92.60 ± 13.703 |
| Week 16 | 93.65 ± 12.849 | 93.94 ± 12.123 |
| Week 20 | 94.35 ± 11.525 | 94.41 ± 12.152 |
| Week 24 | 95.27 ± 9.848 | 93.75 ± 14.314 |
| Week 28 | 95.58 ± 9.663 | 92.96 ± 16.835 |
| Week 32 | 95.74 ± 9.336 | 92.95 ± 16.641 |
| Week 36 | 95.45 ± 11.119 | 92.40 ± 17.125 |
| Week 40 | 95.78 ± 10.456 | 91.77 ± 17.733 |
| Week 44 | 95.45 ± 12.293 | 91.34 ± 18.246 |
| Week 48 | 95.76 ± 11.629 | 90.87 ± 19.181 |
| Week 56 | 93.35 ± 16.116 | 81.67 ± 27.627 |
Collected over Up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Guselkumab 100 mg + Placebo | 0/534 (0%) | 33/534 (6.2%) | 249/534 (46.6%) |
| Secukinumab 300 mg | 0/511 (0%) | 37/511 (7.2%) | 254/511 (49.7%) |
| Event | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 0/534 | 2/511 |
| Atrial FibrillationCardiac disorders | 1/534 | 1/511 |
| Atrioventricular Block CompleteCardiac disorders | 0/534 | 1/511 |
| Cardiac Failure CongestiveCardiac disorders | 0/534 | 1/511 |
| Crohn's DiseaseGastrointestinal disorders | 0/534 | 1/511 |
| HaemorrhoidsGastrointestinal disorders | 0/534 | 1/511 |
| Chest PainGeneral disorders | 0/534 | 1/511 |
| Exercise Tolerance DecreasedGeneral disorders | 0/534 | 1/511 |
| Non-Cardiac Chest PainGeneral disorders | 1/534 | 1/511 |
| CholecystitisHepatobiliary disorders | 0/534 | 1/511 |
| Event | Guselkumab 100 mg + Placebo | Secukinumab 300 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 118/534 | 125/511 |
| Upper Respiratory Tract InfectionInfections and infestations | 83/534 | 92/511 |
| HeadacheNervous system disorders | 48/534 | 48/511 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 30/534 | 25/511 |
| Back PainMusculoskeletal and connective tissue disorders | 29/534 | 18/511 |
| DiarrhoeaGastrointestinal disorders | 27/534 | 20/511 |
Full analysis set (FAS) included all participants randomized at Week 0.
| Age, Categorical(Participants) | Guselkumab 100 mg + Placebo | Secukinumab 300 mg | Total |
|---|---|---|---|
| <=18 years | 6 | 2 | 8 |
| Between 18 and 65 years | 474 | 467 | 941 |
| >=65 years | 54 | 45 | 99 |
| Age, Continuous(years) | Guselkumab 100 mg + Placebo | Secukinumab 300 mg | Total |
|---|---|---|---|
| Mean | 46.3 ± 13.67 | 45.3 ± 13.57 | 45.8 ± 13.63 |
| Sex: Female, Male(Participants) | Guselkumab 100 mg + Placebo | Secukinumab 300 mg | Total |
|---|---|---|---|
| Female | 169 | 172 | 341 |
| Male | 365 | 342 | 707 |
| Ethnicity (NIH/OMB)(Participants) | Guselkumab 100 mg + Placebo | Secukinumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 36 | 63 |
| Not Hispanic or Latino | 502 | 472 | 974 |
| Unknown or Not Reported | 5 | 6 | 11 |
| Race (NIH/OMB)(Participants) | Guselkumab 100 mg + Placebo | Secukinumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 18 | 12 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| Black or African American | 5 | 11 | 16 |
| White | 499 | 480 | 979 |
| More than one race | 4 | 0 | 4 |
| Unknown or Not Reported | 6 | 6 | 12 |
| Region of Enrollment(Participants) | Guselkumab 100 mg + Placebo | Secukinumab 300 mg | Total |
|---|---|---|---|
| AUSTRALIA | 35 | 36 | 71 |
| CANADA | 81 | 77 | 158 |
| CZECH REPUBLIC | 27 | 28 | 55 |
| FRANCE | 28 | 30 | 58 |
| GERMANY | 66 | 56 | 122 |
| HUNGARY | 25 | 20 | 45 |
| POLAND | 119 | 119 | 238 |
| SPAIN | 35 | 33 | 68 |
| UNITED STATES | 118 | 115 | 233 |
Showing the first 100 of 142 sites across 9 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Aug 2018, 15 months.
Results were first posted in Oct 2019, 1 year 1 month after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →